Jan 25 (Reuters) - Spectrum Pharmaceuticals Inc said it would acquire rights to market cancer drug Zevalin outside of the United States from German drugmaker Bayer for 19 million euros ($24.7 million).
Spectrum, which already owns U.S. rights of Zevalin, said Bayer will get royalties based on a percentage of net sales of the drug in all territories worldwide except the United States.
In 2010, Spectrum raked in sales of $29 million from Zevalin.
Zevalin is currently approved in more than 40 countries for the treatment of follicular B-cell non-Hodgkin’s lymphoma.
Shares of Spectrum were trading almost flat at $15.36 on Wednesday on the Nasdaq.
Our Standards: The Thomson Reuters Trust Principles.